Abstract CT170: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Yanrong Jiang, Anna-Maria Militello, Charles Abbott, Bailiang Li, Monika Madrova, Mark Saunders, Jenny Seligmann, Timothy Iveson, Richard Wilson, Janet Graham, Sandra Irvine, Rubina Begum, Reshma Bhat, Gabriel Naylor-Leyland, Andrew Plumb, Austin Obichere, Evelyn Y. Wong, Sean Boyle, Richard Chen, Manuel Rodriguez-Justo, Marnix Jansen, Kai-Keen Shiu
Institutions: University College London, University College London Hospitals NHS Foundation Trust, Personalis (United States), The Christie NHS Foundation Trust, St James's University Hospital, University Hospital Southampton NHS Foundation Trust, University of Glasgow, Beatson West of Scotland Cancer Centre, Cancer Research UK
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154733014